0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Chymopapain: tropical tree to surgical suite Chymopapain

Phil Gunby
JAMA. 1983;249(9):1115-1120. doi:10.1001/jama.1983.03330330005002.
Text Size: A A A
Published online

ABSTRACT

A bit of medical history is being made in connection with the Food and Drug Administration's recent approval of chymopapain to treat so-called slipped disks.

First, take the Nov 10, 1982, decision itself— considered historic because it marks the successful conclusion of a long and sometimes highly controversial struggle to gain official approval for chymopapain.

It's been more than 40 years since the papain enzyme was first isolated (1941). In 1956, author and medical commentator Lewis Thomas, MD, then a pathologist at New York University-Bellevue Medical Center, showed it could break down cartilaginous protein polysaccharide when injected into the tall, rigid ears of rabbits, causing the ears to collapse.

About seven years later, Illinois orthopedic surgeon Lyman Smith, MD, developed chemonucleolysis, a technique in which chymopapain is injected into herniated lumbar intervertebral disks that have not responded to conservative therapy to hasten chondromucoprotein degradation (JAMA 1964;187:137-140). Clinical trials began soon

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();